A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy.

Trial Profile

A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Tivantinib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors ArQule
  • Most Recent Events

    • 11 Oct 2016 Results of post-hoc exploratory analysis (n=98) presented at the 41st European Society for Medical Oncology Congress (2016).
    • 25 Jan 2016 Results presented at the 2016 Gastrointestinal Cancers Symposium, as per ArQule media release.
    • 25 Jan 2016 According to ArQule media release, results were published in The Lancet Oncology medical journal in November 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top